European Organisation for Rare Diseases

European Organisation for Rare Diseases
Established 1997
President
Terkel Andersen

The European Organisation for Rare Diseases (EURORDIS) is a non-governmental patient-driven alliance of patient organizations and individuals active in the field of rare diseases, that promotes research on rare diseases and commercial development of orphan drugs. EURORDIS is a dedicated to improving the quality of life of all people living with rare diseases in Europe. It was founded in 1997; it is supported by its members and by the French Muscular Dystrophy Association (AFM), the European Commission, corporate foundations and the health industry.[1]

There are an estimated 20–30 million people living with rare diseases in Europe alone,[2] and an estimated 6,000 rare diseases. EURORDIS represents more than 700 rare disease organizations in 63 different countries (of which 26 are EU Member States), covering more than 2,000 rare diseases.[1]

EURORDIS is a development of the patient self-advocacy movement, itself widely attributed to AIDS activism.[3]

EURORDIS was the founding partner of Rare Disease Day in 2008 and remains its lead coordinator.[4]

National organizations with a similar focus include National Organization for Rare Disorders (NORD) in the United States, Canadian Organization for Rare Disorders (CORD) in Canada,[5] Allianz Chronischer Seltener Erkrankungen (ACHSE) in Germany, and Federación Española de Enfermedades Raras (FEDER) in Spain.[2]

See also

References

  1. 1 2 http://www.eurordis.org/content/brief-0
  2. 1 2 Nogales Espert A (2004). "[Rare diseases: a new chapter in medicine]". An R Acad Nac Med (Madr) (in Spanish). 121 (1): 139–51; discussion 151–5. PMID 15553406.
  3. Houyez F (2004). "Active involvement of patients in drug research, evaluation, and commercialization: European perspective". J Ambul Care Manage. 27 (2): 139–45. PMID 15069992.
  4. http://www.rarediseaseday.org
  5. http://www.raredisorders.ca

External links

This article is issued from Wikipedia - version of the 4/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.